세계의 저분자 CDMO 시장 : 시장 규모, 점유율 및 동향 분석(제품별, 약제 유형별, 용도별, 지역별), 부문별 예측(2025-2033년)

Small Molecule CDMO Market Size, Share & Trends Analysis Report By Product, By Drug Type, By Application, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

저분자 CDMO 시장 개요

세계 저분자 CDMO 시장은 2024년 713억 달러로 평가되었습니다. 2033년에는 1,262억 달러에 달하고, 2025-2033년 연평균 6.7%의 성장률을 보일 것으로 예측됩니다.

이 시장의 성장은 전략적 아웃소싱 트렌드, 탄탄한 제약 파이프라인, 세계 제조 전환의 수렴에 기인합니다.

제약 및 생명공학 기업들은 R&D 비용의 합리화, 시장 출시 시간 단축, 특히 고활성 원료의약품 및 복잡한 화학물질에 특화된 역량을 활용하기 위해 CDMO에 대한 의존도를 높이고 있습니다. 특히 암, 감염성 질환, 심장병 등의 치료 분야에서 저분자 의약품의 지속적인 승인은 임상 및 상업적 규모의 생산에 대한 강력한 수요를 뒷받침하고 있습니다.

이 시장을 주도하는 것은 의약품 혁신의 진화와 의약품 개발의 경제 상황의 변화입니다. R&D, 스케일업, GMP 제조를 위한 내부 인프라를 갖추지 못한 경우가 많은 생명공학 기업이나 가상 제약회사의 출현이 시장 성장의 원동력이 되고 있습니다. 이들 기업들은 CDMO를 단순한 공급업체가 아닌, 자사의 분자를 신속하고 컴플라이언스에 맞게 출시하기 위한 전략적 협력자로 활용하고 있습니다. 아웃소싱이 비용 중심이었던 과거와 달리 오늘날의 계약은 점점 더 혁신 중심이 되어 전문 공정 화학, 제형 과학 및 규제에 대한 지식을 CDMO에 의존하고 있습니다. 이러한 변화는 항체 약물 복합체(ADC), HPAPI, 표적 항암제 등 제조의 복잡성과 봉쇄의 필요성이 높은 고가 저분자 개발에서 특히 두드러지게 나타나고 있습니다.

또한, CDMO 생태계의 디지털화 및 첨단 제조 기술로의 전환 추세도 시장 성장에 기여하고 있습니다. AI 기반 예측 모델링, 연속 흐름 처리, 실시간 릴리스 테스트(RTRT)는 저분자 제조의 비용 효율성과 유연성을 혁신하고 있습니다. 이러한 혁신을 통해 CDMO는 제품을 차별화하고, 배치 수율을 향상시키며, 더 빠르고 데이터가 풍부한 환경에서 품질 요구 사항을 충족시킬 수 있습니다. 또한, 대형 제약사들은 공급망에 지속가능성을 요구하고 있으며, 그린 케미스트리 역량을 갖춘 CDMO나 저탄소 생산을 실천하는 CDMO는 더욱 매력적인 파트너가 되고 있습니다. 시장은 또한 지정학적 불안정과 의약품 부족으로 인한 공급망 전략의 지역적 변화로 인해 북미 제약사들은 공급업체 기반을 다변화하고, 중복 생산 능력을 갖춘 북미 및 유럽 CDMO를 찾고 있습니다.

목차

제1장 분석 방법, 범위

제2장 주요 요약

제3장 저분자 CDMO 시장 : 변동 요인, 동향 및 범위

• 시장 연관 전망
• 저분자 CDMO 시장 역학
• 기술 상황
• 가격 모델 분석
• 임상시험 볼륨 분석
• 저분자 CDMO 시장 : 분석 툴

제4장 저분자 CDMO 시장 : 제품별 추정 및 동향 분석

• 부문 대시보드
• 저분자 CDMO 시장 : 제품별 변동 분석
• 저분자 CDMO 시장 : 시장 규모 예측과 동향 분석, 제품별(2021-2033년)
• 원료 의약품(API)
• 완성 의약품

제5장 저분자 CDMO 시장 : 약제 유형별 추정 및 동향 분석

• 부문 대시보드
• 세계의 저분자 CDMO 시장 : 약제 유형별 변동 분석
• 세계의 저분자 CDMO 시장 : 시장 규모 예측과 동향 분석, 약제 유형별(2021-2033년)
• 혁신기업
• 제네릭 의약품

제6장 저분자 CDMO 시장 : 용도별 추정 및 동향 분석

• 부문 대시보드
• 저분자 CDMO 시장 : 용도별 변동 분석
• 저분자 CDMO 시장 : 시장 규모 예측과 동향 분석, 용도별(2021-2033년)
• 종양
• 심혈관 질환
• 중추신경계(CNS) 질환
• 자가면역 질환/염증
• 기타

제7장 저분자 CDMO 시장 : 지역별 추정, 동향 분석(제품별, 약제 유형별, 용도별)

• 지역별 시장 대시보드
• 세계 시장 스냅숏 : 지역별
• 시장 규모 예측과 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
  • 시장 리더
  • 신규 기업
• 저분자 CDMO 시장 점유율/평가 분석(2024년)
• 기업 개요
  • Lonza
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Cambrex Corporation
  • Bellen Chemistry
  • Siegfried Holding AG
  • Recipharm AB
  • Eurofins Scientific
  • Aurigene Pharmaceutical Services Ltd
  • CordenPharma International

LSH

영문 목차

영문목차

Small Molecule CDMO Market Summary

The global small molecule CDMO market was estimated at USD 71.3 billion in 2024 and is projected to reach USD 126.2 billion by 2033, growing at a CAGR of 6.7% from 2025 to 2033. The growth of the market is due to a convergence of strategic outsourcing trends, robust pharmaceutical pipelines, and global manufacturing shifts.

Pharmaceutical and biotech companies increasingly rely on CDMOs to streamline R&D costs, accelerate time-to-market, and access specialized capabilities, particularly for highly potent APIs and complex chemistries. The consistent approval of small molecule drugs, especially in therapeutic areas such as oncology, infectious diseases, and cardiology, sustains strong demand for both clinical and commercial-scale manufacturing.

The market is driven by the evolving nature of pharmaceutical innovation and the changing economic landscape of drug development. The emergence of biotech firms and virtual pharma companies, which often lack in-house infrastructure for R&D, scale up, or GMP manufacturing, is driving the market growth. These companies are turning to CDMOs not just as suppliers but as strategic collaborators to bring their molecules to market quickly and compliantly. Unlike in the past where outsourcing was cost-driven, today's engagements are increasingly innovation-driven-relying on CDMOs for specialized process chemistry, formulation science, and regulatory knowledge. This shift is particularly evident in the development of high-value small molecules such as antibody-drug conjugates (ADCs), HPAPIs, and targeted oncology drugs, where manufacturing complexity and containment needs are high.

Moreover, the growing trend towards digitalization and advanced manufacturing technologies within the CDMO ecosystem is also contributing to market growth.AI-driven predictive modeling, continuous flow processing, and real-time release testing (RTRT) are transforming the cost-efficiency and flexibility of small molecule production. These innovations allow CDMOs to differentiate their offerings, improve batch yields, and meet quality requirements in a faster, more data-rich environment. In addition, large pharmaceutical companies are seeking sustainability in their supply chains, and CDMOs with green chemistry capabilities or low-carbon production practices are becoming more attractive partners. The market is also benefiting from regional shifts in supply chain strategy due to geopolitical instability and drug shortages-prompting Western pharma firms to diversify their supplier base and seek CDMOs in North America and Europe with redundant capacity.

Global Small Molecule CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule CDMO market report based on product, drug type, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Active Pharmaceutical Ingredients (API)
• Finished Drug Products
• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Innovators
• Generics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Disease
• Central Nervous System (CNS) Conditions
• Autoimmune/Inflammation
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Small Molecule CDMO Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Small Molecule CDMO Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Clinical Trials Volume Analysis
• 3.6. Small Molecule CDMO Market: Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Small Molecule CDMO Market Product Movement Analysis
• 4.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Active Pharmaceutical Ingredients (API)
  • 4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Finished Drug Products
  • 4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD million)

Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Small Molecule CDMO Market Drug Type Movement Analysis
• 5.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
• 5.4. Innovators
  • 5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Generics
  • 5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Small Molecule CDMO Market Application Movement Analysis
• 6.3. Global Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Cardiovascular Disease
  • 6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Central Nervous System (CNS) Conditions
  • 6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Autoimmune/Inflammation
  • 6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Small Molecule CDMO Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Catalent, Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Thermo Fisher Scientific Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Cambrex Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bellen Chemistry
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Siegfried Holding AG
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Recipharm AB
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Eurofins Scientific
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Aurigene Pharmaceutical Services Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. CordenPharma International
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives

관련자료